Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results
Canopy Growth Corp (CGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets Cannabis Net revenue growth of 30% in Cannabis segment 18% growth in Canada medical cannabis revenue and 17% growth in C
How this was made
The 30-second read
Why it matters
The earnings release provides new financial data that could move the stock modestly; investors will focus on revenue growth versus persistent losses.
Market read
First‑time earnings disclosure for the quarter; provides fresh data for traders evaluating CGC's valuation and sector trends.
What to watch
The reduction in Veterans Affairs Canada reimbursement and inventory step‑up charges may pressure margins more than headline growth suggests.
Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets
Net revenue increased 22% and Cannabis net revenue increased 30%, led by 141% international markets cannabis growth, while consolidated gross margin declined to 29% from 33% and net loss increased to $40,694 (in thousands of Canadian dollars) following fair value charges on Canopy USA related assets.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net revenue, three months ended September 30, 2026GAAP | CA$81.37M | – | 22% |
| Revenue, three months ended September 30, 2026GAAP | CA$99.51M | – | – |
| Excise taxes, three months ended September 30, 2026GAAP | CA$18.13M | – | – |
| Cost of goods sold, three months ended September 30, 2026GAAP | CA$58.02M | – | – |
| Gross margin, three months ended September 30, 2026GAAP | CA$23.36M | – | – |
| Gross margin percentage, three months ended September 30, 2026GAAP | 29% | – | – |
| Adjusted gross margin, three months ended September 30, 2026non-GAAP | CA$25.40M | – | – |
| Adjusted gross margin percentage, three months ended September 30, 2026non-GAAP | 31% | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | CA$39.69M | – | 9% higher |
| Share-based compensation, three months ended September 30, 2026GAAP | CA$4.03M | – | – |
| Loss on asset impairment and restructuring, three months ended September 30, 2026GAAP | CA$2.59M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | CA$46.32M | – | – |
| Operating loss, three months ended September 30, 2026GAAP | −CA$22.96M | – | – |
| Other income (expense), net, three months ended September 30, 2026GAAP | −CA$18.53M | – | – |
| Loss before income taxes, three months ended September 30, 2026GAAP | −CA$41.49M | – | – |
| Income tax recovery (expense), three months ended September 30, 2026GAAP | CA$800K | – | – |
| Net loss, three months ended September 30, 2026GAAP | −CA$40.69M | – | increased by $35.7 million |
| Basic and diluted loss per share, three months ended September 30, 2026GAAP | $(0.10) | – | – |
| Basic and diluted weighted average common shares outstanding, three months ended September 30, 2026GAAP | 423,109,807 | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | −CA$2.88M | – | improvement of $0.2M or 6% |
| Net cash used in operating activities, three months ended September 30, 2026GAAP | −CA$12.57M | – | – |
| Purchases of and deposits on property, plant and equipment, three months ended September 30, 2026GAAP | −CA$2.98M | – | – |
| Free cash flow, three months ended September 30, 2026non-GAAP | −CA$15.55M | – | decreased from $19.2M in Q2 FY2026 to $15.5M in Q2 FY2027 |
| Net cash used in operating activities, six months ended September 30, 2026GAAP | −CA$37.58M | – | – |
| Purchases of and deposits on property, plant and equipment, six months ended September 30, 2026GAAP | −CA$3.71M | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | CA$247.3M | – | – |
| Short-term investments, September 30, 2026GAAP | CA$72.45M | – | – |
| Current portion of long-term debt, September 30, 2026GAAP | CA$43.13M | – | – |
| Long-term debt, September 30, 2026GAAP | CA$202.7M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| CannabisGrowth was led by Canadian medical cannabis, Canadian adult-use cannabis and international markets cannabis. | CA$66.23M | – | 30% |
| Canadian adult-use cannabisPrimarily attributable to increased flower sales driven by the acquisition of MTL Cannabis, partially offset by declines in opportunistic bulk sales. | CA$28.13M | – | 17% |
| Canadian medical cannabisDriven by growth in the number of insured customers and the acquisition of MTL Cannabis, partially offset by the Canadian government’s reduction in the Veterans Affairs Canada reimbursement rate for medical cannabis. | CA$25.84M | – | 18% |
| International markets cannabisPrimarily due to strong sales in Europe, specifically in Germany and Poland. | CA$12.27M | – | 141% |
| Storz & BickelThe decrease is primarily attributable to decreased customer spending on Storz & Bickel products in certain geographic regions. | CA$15.14M | – | (4%) |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
What drove it
- International markets cannabis net revenue increased 141%, primarily due to strong sales in Germany and Poland.
- Canadian medical cannabis net revenue increased 18%, driven by insured-customer growth and the MTL Cannabis acquisition.
- Canadian adult-use cannabis net revenue increased 17%, primarily due to increased flower sales driven by the MTL Cannabis acquisition.
- The Smiths Falls facility received EU GMP certification, and the Kincardine cultivation facility received renewed EU GMP certification.
- The Company expanded medical cannabis supply into the United Kingdom and broadened its Australian medical cannabis portfolio.
Concerns
- Consolidated gross margin percentage declined to 29% from 33%, and adjusted gross margin percentage declined to 31% from 33%.
- Cannabis adjusted gross margin percentage declined to 29% from 31%, primarily attributable to the reduction in the VAC reimbursement rate available for medical cannabis.
- Storz & Bickel net revenue declined 4% due to decreased customer spending in certain geographic regions.
- Net loss increased by $35.7 million due to $35.8 million of fair value charges on Canopy USA related assets.
- The filing identifies a material weakness in internal control over financial reporting and references the March 31, 2026 restatement of consolidated financial statements.
What to watch
- Progress toward reporting positive adjusted EBITDA during fiscal 2027.
- The impact of the VAC reimbursement-rate reduction on Cannabis segment gross margin.
- International medical cannabis sales momentum in Germany, Poland, the United Kingdom and Australia.
- Cultivation consistency and output improvements from capital expenditures at production facilities.
- Customer spending trends for Storz & Bickel products in certain geographic regions.
Balance sheet and cash flow
- Cash and cash equivalents were $247,340 (in thousands of Canadian dollars) at September 30, 2026, compared with $364,683 (in thousands of Canadian dollars) at March 31, 2026.
- Short-term investments were $72,451 (in thousands of Canadian dollars) at September 30, 2026, compared with - at March 31, 2026.
- Current portion of long-term debt was $43,130 (in thousands of Canadian dollars) at September 30, 2026, compared with $16,237 (in thousands of Canadian dollars) at March 31, 2026.
- Long-term debt was $202,734 (in thousands of Canadian dollars) at September 30, 2026, compared with $217,123 (in thousands of Canadian dollars) at March 31, 2026.
- Net cash used in operating activities was $(37,581) (in thousands of Canadian dollars) for the six months ended September 30, 2026, compared with $(28,316) (in thousands of Canadian dollars) for the six months ended September 30, 2025.
- Net decrease in cash and cash equivalents was $(117,343) (in thousands of Canadian dollars) for the six months ended September 30, 2026, compared with net increase in cash and cash equivalents of $184,247 (in thousands of Canadian dollars) for the six months ended September 30, 2025.
Analysis
Canopy Growth reported $81,373 (in thousands of Canadian dollars) of net revenue for Q2 FY2027, versus $66,683 (in thousands of Canadian dollars) in Q2 FY2026. The Cannabis segment generated $66,235 (in thousands of Canadian dollars), up 30%, while Storz & Bickel generated $15,138 (in thousands of Canadian dollars), down 4%. International markets cannabis was the largest growth contributor, increasing 141% to $12,268 (in thousands of Canadian dollars), with the company attributing the increase to Europe, specifically Germany and Poland.
Canadian medical cannabis revenue was $25,840 (in thousands of Canadian dollars), up 18%, supported by insured-customer growth and the MTL Cannabis acquisition. Canadian adult-use cannabis revenue was $28,127 (in thousands of Canadian dollars), up 17%, primarily from increased flower sales associated with MTL Cannabis. The MTL transaction also increased selling, general and administrative expenses, which were $39,693 (in thousands of Canadian dollars), 9% higher than the prior-year period, although the company cited headcount reductions and other cost initiatives as offsets.
Margin performance deteriorated despite revenue growth. Consolidated gross margin percentage was 29%, compared with 33%, and adjusted gross margin percentage was 31%, compared with 33%. Cannabis gross margin percentage was 26%, compared with 31%, and its adjusted gross margin percentage was 29%, compared with 31%. Management attributed the Cannabis adjusted-margin decline primarily to the lower VAC reimbursement rate. Storz & Bickel gross margin percentage improved to 39% from 38% despite lower revenue, which the company attributed to cost efficiencies and product mix.
Net loss was $(40,694) (in thousands of Canadian dollars), compared with $(4,978) (in thousands of Canadian dollars), as the company cited $35.8 million of fair value charges on Canopy USA related assets. Adjusted EBITDA improved to $(2,878) (in thousands of Canadian dollars) from $(3,049) (in thousands of Canadian dollars). Free cash flow was $(15,547) (in thousands of Canadian dollars), compared with $(19,205) (in thousands of Canadian dollars), while cash and cash equivalents stood at $247,340 (in thousands of Canadian dollars) at September 30, 2026.
The release did not provide quantified financial guidance. Management stated that it is within reach of reporting positive adjusted EBITDA during fiscal 2027. Operationally, the company expanded its EU GMP-certified supply chain through Smiths Falls certification, renewed Kincardine certification, entered the United Kingdom medical market through GROW Group U.K. Ltd., and broadened its Australian medical cannabis portfolio. These initiatives place international execution, Cannabis margins and the path from adjusted EBITDA loss to positive adjusted EBITDA at the center of the reported outlook.
Management, verbatim
We have made tremendous progress on our international strategy. Our international business delivered 141% net revenue growth in the second quarter of fiscal year 2027 driven by strong medical cannabis sales in Germany and Poland. We entered the U.K. market, added to our German leadership team, broadened our product portfolio in Australia and expanded our end-to-end EU GMP-certified supply chain through the certification of our Smiths Falls facility. We expect the ongoing elevation of our cultivation capabilities to drive our momentum further across the entire business.
Luc Mongeau, Chief Executive Officer
We reported another quarter of strong net revenue growth, including a 17% year-over-year increase in Canada adult-use cannabis, an 18% increase in Canada medical cannabis and 30% growth in the Cannabis segment overall. We are progressing steadily to profitability, quarter after quarter. Our disciplined approach continues to show improvements in adjusted EBITDA 1 compared to Q2 FY2026, placing us within reach of reporting positive adjusted EBITDA during fiscal 2027.
Tom Stewart, Chief Financial Officer
Not in the filing
stated, not guessed- Quantified forward financial guidance for revenue, gross margin, operating expenses, tax rate, adjusted EBITDA or cash flow was not provided.
- Prior outlook was not provided.
- Dividends and share repurchases were not reported.
- GAAP operating income was not reported because the company reported operating loss.
- Adjusted EPS was not reported.
- Quarterly cash balance comparison with the immediately preceding quarter was not reported.
- Segment operating income or loss was not reported.
- Operating margin was not reported.
- Net debt was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Canopy Growth (NASDAQ: CGC, TSX: WEED) released its Q2 FY2027 earnings, highlighting international expansion and EU GMP certification.
Ticker impact
Canopy Growth filed an 8‑K reporting Q2 FY2027 results with 22% revenue growth and adjusted EBITDA loss narrowing.
likely modest upside as the market prices in revenue growth, but pressure from higher expenses and a net loss.
The earnings release provides fresh financial metrics; growth beats expectations, yet the loss and expense increase temper enthusiasm.
Market effects
Positive momentum for the cannabis sector as international sales surge, but sector still faces regulatory headwinds.
European cannabis markets may see increased investor interest due to EU GMP certification and German sales growth.
Limited to cannabis investors; broader market impact is minimal.
Counterpoint
Despite revenue growth, the widening net loss and higher SG&A could signal deeper cost issues, suggesting a short bias.
Key entities
- CompanyCanopy Growth Corp
Global cannabis producer reporting Q2 FY2027 results.
- CompanyMTL Cannabis Corp
Acquired by Canopy Growth, contributing to Canadian sales growth.



